Related Experiment Videos
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering
P J Goadsby1, M D Ferrari, J Olesen
1Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK. peterg@brain.ion.ucl.ac.uk
Neurology
|January 15, 2000
Summary
Eletriptan at 40 mg and 80 mg showed superior efficacy for acute migraine treatment compared to sumatriptan and placebo. Both medications were well-tolerated, with mild to moderate adverse events.
Area of Science:
- Neurology
- Pharmacology
Background:
- Eletriptan is a selective 5HT1B/1D receptor agonist with demonstrated antimigraine activity in preclinical models.
- Pharmacokinetic studies show eletriptan has rapid and linear oral absorption in healthy volunteers.
Purpose of the Study:
- To evaluate the efficacy, safety, and tolerability of oral eletriptan (20 mg, 40 mg, 80 mg) versus oral sumatriptan (100 mg) and placebo.
- The study aimed to determine the best dosage for acute migraine treatment.
Main Methods:
- A randomized, double-blind, parallel-group study involving 857 outpatients diagnosed with migraine.
- Participants received placebo, 100 mg sumatriptan, or 20 mg, 40 mg, or 80 mg eletriptan for acute migraine.
- The primary endpoint was headache response at 2 hours post-treatment.
Main Results:
- Headache response rates at 2 hours: placebo 24%, sumatriptan 55%, eletriptan 20 mg (54%), 40 mg (65%), and 80 mg (77%).
- Eletriptan (40 mg and 80 mg) demonstrated superior headache-free rates compared to sumatriptan and placebo.
- All eletriptan doses showed statistically significant improvement over placebo (p<0.001).
Conclusions:
- Eletriptan, particularly at 40 mg and 80 mg, is more effective than sumatriptan for acute migraine treatment.
- Selected doses of eletriptan offer improved efficacy, faster onset, and better patient acceptance.
- Both eletriptan and sumatriptan were found to be safe and well-tolerated.